On June 9, 2026, during the 11th Advanced Therapy Innovation Summit (ATMP 2026), Frost & Sullivan (hereinafter referred to as “Frost & Sullivan”) in collaboration withCytivaand other industry partnerspublished the ‘In vivo CAR-T Industry Blue Book’in Guangzhou.
Mr. Mao Hua, Senior Partner and Managing Director of Frost & Sullivan, Ms. Song Rongli, General Manager and Scientific Founder of Chengdu Wishen Biopharmaceutical Technology Co., Ltd., Mr. Zhang Yongke, Chief Scientist and Senior Vice President of Nanjing Reindeer Biology, Mr. Wang Yamin, COO of Shenzhen Hongxin Biotech Co., Ltd., Mr. Zhang Shuren, COO of Shenzhen Puijiu Biopharmaceutical Co., Ltd., Mr. Xue Bofu, CSO of Shenzhen Shenyan Biotech Co., Ltd., Mr. Meng Weian, CTO of Yunzhou Biotech (Guangzhou) Co., Ltd., Ms. Luo Fang, General Manager of Cytiva Gene Drug Operations, and Ms. Sun Yingying, Senior Director of Cytiva China and Strategy, attended and witnessed the release of the ‘Blue Book’.
At the release ceremony,Mr. Mao Hua, Senior Partner and Managing Director of Frost & Sullivanprovided a brief interpretation of the main contents of the ‘In vivo CAR-T Industry Blue Book’.
🌟Key contents of the Blue Book are presented below🌟
✓Review of the development path of cell immunotherapy
✓Positioning of in vivo CAR-T technology
✓Comparison of technical approaches (viral vs. non-viral)
✓Clinical and industrial trends of in vivo CAR-T
✓Industry significance and future prospects
Ms. Luo Fang, General Manager of Cytiva Gene Drug Operations, explained the purpose of compiling the Blue Book by Cytiva as the initiator, and Dr. Zhang Yongke, Chief Science Officer and Senior Vice President of Reindeer Biology, shared his outlook on the development prospects of in vivo CAR-T technology.
Ms. Luo Fang, General Manager of Cytiva Gene Drug Operations:
The most valuable aspect of the In vivo CAR-T Industry Blue Book is not the content itself, but its “collective nature”. It brings together real experiences and long-term thoughts from the industry, academia, and clinical fields, representing the common understanding of scientists, doctors, enterprises, and ecosystem partners. In such a rapidly changing frontier field:No single institution can define the future alone, but through consensus, we can get closer to the future.
Dr. Zhang Yongke, Chief Science Officer and Senior Vice President of Reindeer Biology, said:
as a representative cutting-edge technology of next-generation CAR-T, in vivo CAR-T is making a crucial transition from proof of concept to clinical validation; its indications have expanded from blood cancer and autoimmune diseases to solid tumors. The dual evolution of technology and clinical researchmeans that in vivo CAR-T is gradually ready for large-scale and accessible applications.
Frost & Sullivan and Cytiva hope that the release of this ‘Blue Book’ will provide a more systematic research reference and communication foundation for all parties in the industry. Together with the industry, academia, investment institutions, and clinical fields, we will focus on the long-term development of in vivo CAR-T technology and drive the global cell therapy industry to a new stage.
Here, we would like to express our gratitude to the following co-signatories for their strong support in industry exchanges, technical discussions, and industrial practice sharing (sorted by the first letter of the company name):
■ Bluepeak Partner LLC
■ Chengdu Wishen Biopharmaceutical Technology Co., Ltd.
■ Chengdu Zhenyu Biopharmaceutical Technology Co., Ltd.
■ Purbing Biotech, a subsidiary of Genentech Co., Ltd.
■ Nanjing Reindeer Biotechnology Co., Ltd.
■ Shanghai Heyuan Biotechnology (Group) Co., Ltd.
■ Shanghai Zhaowei Technology Development Co., Ltd.
■ Shenzhen Hongxin Biotech Co., Ltd.
■ Shenzhen Puijiu Biopharmaceutical Co., Ltd.
■ Shenzhen Shenyan Biotech Co., Ltd.
■ Yunzhou Biotech (Guangzhou) Co., Ltd.
At the same time, we would like to express our sincere thanks to the experts who provided professional guidance and cutting-edge insights during the preparation of the Blue Book (sorted by the first letter of the name):
■Professor Chen Zhu
Director and Chief Physician of the Rheumatology and Immunology Department at the First Affiliated Hospital of the Chinese Academy of Sciences (Anhui Provincial Hospital)
■Dr. Xianghong Li
Bluepeak Managing Director & Partner
■Professor Shen Lin
Director of the Digestive Oncology Department at Peking University Cancer Hospital, Director of Phase I Clinical Ward, and Director of the Beijing Key Laboratory of Solid Tumor Cells and Gene Therapy
■Professor Wang Shuhang
Chief Physician at the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor at the National Cancer Center of the Chinese Academy of Medical Sciences
■Professor Yang Hanbo
Founder of Zhenyu Biotech and leader of the cell engineering technology direction of the “Minshan Action” program
■Professor Zhang Yi
Biocell Therapy Center at the First Affiliated Hospital of Zhengzhou University
